Enlivex (ENLV) vs XTL Biopharmaceuticals (XTLB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Enlivex is the larger company by market cap ($5.1 million vs $4.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENLV | XTLB |
|---|---|---|
| Share price | $0.254 | $1.98 |
| Market cap | $5.06M | $4.87M |
| 1-day change | -8.30% | 0.00% |
| P/E ratio (TTM) | 0.00 | — |
| EPS (TTM) | $494.00 | $-0.36 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.15 | $6.24 |
| 52-week low | $0.224 | $1.97 |
| Distance from 52-week high | -99.06% | -68.27% |
| Analyst consensus | none | — |
| Avg. price target upside | +31396.06% | — |
| Average volume | 950.55K | 8.50K |
| Shares outstanding | 19.91M | 2.46M |
| Employees | 34 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Enlivex
ENLV stock →Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 34 employees
About XTL Biopharmaceuticals
XTLB stock →XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
ENLV vs XTLB FAQ
Which is bigger, Enlivex or XTL Biopharmaceuticals?
Enlivex (ENLV) is larger, with a market capitalization of $5.06M compared with $4.87M for XTL Biopharmaceuticals (XTLB).
Are Enlivex and XTL Biopharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.